SLC5A2 and type 2 diabetes mellitus: Several clinical studies investigating the short- to intermediate-term effects of SGLT2 inhibitor therapy on estimated fluid volume parameters have previously demonstrated a gradual reduction in those parameters following SGLT2 inhibitor administration, which was maintained for several weeks in patients with type 2 diabetes mellitus (T2DM) or HF [10–15].